ZTS · Large Cap · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Free AI brief
Free to track. No card required. Usually ready in 10-15 minutes.
Price, momentum, and the numbers behind the story.
Stocksbrew score
63/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Current price
$72.88
Lowest
$80
Median target
$94
Highest
$155
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Forward P/E
Favorable · 44% below avg
11.55x
Price / FCF
Strong · Cash flow supports price
12.74x
EV / EBITDA
Strong · Earnings support price
9.12x
ROIC
Strong · Excellent capital returns
27.3%
ROE
Favorable · 67.0% - strong capital efficiency
64.9%
Current ratio
Strong · Good liquidity position
3.08x
Debt / equity
Needs attention · Unfavorable
2.94x
ZTS against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $29.50B | 11.8 | +1.6% | 63 | |
| $9.95B | 18.9 | +19.7% | 78 | |
| $33.72B | 35.3 | +15.5% | 78 | |
| $4.12B | 12.4 | +13.5% | 78 | |
| $1.09T | 39.2 | +49.6% | 77 |
Every story that touched the stock this week, newest first.